Suven Life Sciences Ltd has secured one product patent each from Eurasia, Japan and one from Mexico for its New Chemical Entities (NCEs).
The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company and were being developed as therapeutic agents.
“`They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia,’’ Suven said in a release issued here on Tuesday.
With these new patents, Suven has 13 patents from Eurasia, 12 from Japan and 17 from Mexico. Business Line
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…